June 9, 2020
As lockdown measures begin to ease in France, people with neurological or psychiatric diseases are still at risk from Covid-19.
To support these patients, Ad Scientiam, a startup based in the iPEPS - The Healthtech Hub incubator of the Paris Brain Institute, is accelerating the rollout of MSCopilot®, the first CE-marked medical device for monitoring patients with multiple sclerosis.
What is the most appropriate method in clinical studies? We explore the differences between association and agreement for comparing two measurement methods.
September 13, 2022
Parallel categories representations allow visualizing relationships between multiple categorical variables. Discover how we use them at Ad Scientiam.
April 11, 2022
After 8 years of existence, our old logo gives way to a brand new, more dynamic and modern logo. Our UI designer Ilan Verdier explains the origin of these changes.
March 30, 2022
Talk to our experts and discover how our solutions integrate into your practice or studies.
This site uses analytics cookies
We use Countly to measure audience and improve your experience. This data remains anonymous and is not shared with third parties.